Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-Sep-24 9:21 PM View:  | Singleton J Matthew Director | Viking Therapeutics, Inc. (VKTX) | 20-Sep-24 | Planned Option Sale | 10,300 | $69.50 | $715,850.00 | (52%) 19.8K to 9.5K | |
| 20-Sep-24 9:20 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 20-Sep-24 | Option Exercise | 166,130 | $7.77 | $1,290,830.00 | 7% 2.35M to 2.52M | |
| 20-Sep-24 9:20 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 20-Sep-24 | Sale (Planned) | 50,000 | $70.83 | $3,541,520.00 | (2%) 2.35M to 2.3M | |
| 20-Sep-24 9:21 PM View: | Singleton J Matthew Director | Viking Therapeutics, Inc. (VKTX) | 20-Sep-24 | Option Exercise | 10,300 | $1.19 | $12,257.00 | 108% 9.5K to 19.8K | |
| 20-Sep-24 9:20 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 20-Sep-24 | Planned Option Sale | 166,130 | $70.83 | $11,767,000.00 | (7%) 2.52M to 2.35M | |
| 22-Aug-24 7:23 PM View: | Singleton J Matthew Director | Viking Therapeutics, Inc. (VKTX) | 21-Aug-24 | Option Exercise | 5,700 | $1.19 | $6,783.00 | 60% 9.5K to 15.2K | |
| 22-Aug-24 7:23 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 21-Aug-24 | Planned Option Sale | 1,000 | $69.90 | $69,900.00 | (< 1%) 2.36M to 2.35M | |
| 22-Aug-24 7:23 PM View: | Singleton J Matthew Director | Viking Therapeutics, Inc. (VKTX) | 21-Aug-24 | Planned Option Sale | 5,700 | $69.72 | $397,430.00 | (38%) 15.2K to 9.5K | |
| 22-Aug-24 7:23 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 21-Aug-24 | Option Exercise | 1,000 | $7.77 | $7,770.00 | < 1% 2.35M to 2.36M | |
| 14-Aug-24 8:03 PM View: | Singleton J Matthew Director | Viking Therapeutics, Inc. (VKTX) | 14-Aug-24 | Option Exercise | 20,786 | $8.00 | $166,288.00 | 219% 9.5K to 30.29K | |
| 14-Aug-24 8:03 PM View: | Singleton J Matthew Director | Viking Therapeutics, Inc. (VKTX) | 14-Aug-24 | Planned Option Sale | 20,786 | $57.53 | $1,195,740.00 | (69%) 30.29K to 9.5K | |
| 31-Jul-24 4:05 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 30-Jul-24 | Sale | 18,026 | $57.13 | $1,029,910.00 | (5%) 380.18K to 362.15K | |
| 31-Jul-24 4:05 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 30-Jul-24 | Sale | 16,136 | $57.15 | $922,212.00 | (8%) 203.19K to 187.05K | |
| 31-Jul-24 4:05 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 30-Jul-24 | Sale | 115,859 | $57.58 | $6,670,600.00 | (5%) 2.47M to 2.35M | |
| 31-Jul-24 4:05 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 29-Jul-24 | Grant | 28,334 | -- | -- | 16% 174.85K to 203.19K | |
| 31-Jul-24 4:05 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 29-Jul-24 | Grant | 204,333 | -- | -- | 9% 2.27M to 2.47M | |
| 31-Jul-24 4:05 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 29-Jul-24 | Grant | 31,667 | -- | -- | 9% 348.51K to 380.18K | |
| 03-May-24 8:51 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-May-24 | Planned Option Sale | 34,249 | $74.69 | $2,558,060.00 | (14%) 241.61K to 207.36K | |
| 03-May-24 8:51 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-May-24 | Option Exercise | 34,249 | $4.86 | $166,285.00 | 17% 207.36K to 241.61K | |
| 03-May-24 8:51 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-May-24 | Sale (Planned) | 32,507 | $74.69 | $2,427,950.00 | (16%) 207.36K to 174.85K | |
| 02-May-24 9:27 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-May-24 | Option Exercise | 281,425 | $6.18 | $1,740,580.00 | 81% 348.51K to 629.93K | |
| 02-May-24 9:27 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-May-24 | Planned Option Sale | 281,425 | $78.66 | $22,136,500.00 | (45%) 629.93K to 348.51K | |
| 27-Mar-24 8:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Grant | 31,667 | -- | -- | 16% 192.3K to 223.97K | |
| 27-Mar-24 8:51 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Payment of Exercise | 153,948 | $83.34 | $12,830,000.00 | (6%) 2.42M to 2.27M | |
| 27-Mar-24 8:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Grant | 31,667 | -- | -- | 9% 348.51K to 380.18K | |
| 27-Mar-24 8:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Payment of Exercise | 16,610 | $83.34 | $1,384,280.00 | (7%) 223.97K to 207.36K | |
| 27-Mar-24 8:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Payment of Exercise | 16,610 | $83.34 | $1,384,280.00 | (4%) 380.18K to 363.56K | |
| 27-Mar-24 8:51 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Grant | 221,667 | -- | -- | 10% 2.2M to 2.42M | |
| 04-Mar-24 7:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Grant | 31,667 | -- | -- | 9% 333.8K to 365.47K | |
| 04-Mar-24 7:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Payment of Exercise | 20,093 | $85.22 | $1,712,330.00 | (9%) 212.4K to 192.3K | |
| 04-Mar-24 7:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Payment of Exercise | 16,958 | $85.22 | $1,445,160.00 | (5%) 365.47K to 348.51K | |
| 04-Mar-24 7:54 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Grant | 221,667 | -- | -- | 10% 2.14M to 2.36M | |
| 04-Mar-24 7:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Grant | 31,667 | -- | -- | 18% 180.73K to 212.4K | |
| 04-Mar-24 7:54 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Payment of Exercise | 162,815 | $85.22 | $13,875,100.00 | (7%) 2.36M to 2.2M | |
| 09-Feb-24 8:59 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 09-Feb-24 | Private Sale (Planned) | 45,000 | $29.90 | $1,345,500.00 | (2%) 2.18M to 2.14M | |
| 08-Feb-24 7:38 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Planned Option Sale | 25,000 | $28.05 | $701,250.00 | (100%) 25.0K to 0 | |
| 08-Feb-24 7:40 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Option Exercise | 189,079 | $3.76 | $711,367.00 | 8% 2.26M to 2.45M | |
| 08-Feb-24 7:40 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Planned Option Sale | 189,079 | $26.87 | $5,081,000.00 | (8%) 2.45M to 2.26M | |
| 08-Feb-24 7:38 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Option Exercise | 25,000 | $8.32 | $208,000.00 | 100% 0 to 25.0K | |
| 08-Feb-24 7:40 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Sale (Planned) | 80,000 | $26.87 | $2,149,790.00 | (4%) 2.26M to 2.18M | |
| 31-Jan-24 8:39 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 31-Jan-24 | Option Exercise | 85,000 | $1.23 | $104,550.00 | 4% 2.26M to 2.35M | |
| 31-Jan-24 8:39 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 31-Jan-24 | Planned Option Sale | 85,000 | $24.71 | $2,100,750.00 | (4%) 2.35M to 2.26M | |
| 30-Jan-24 9:05 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 30-Jan-24 | Option Exercise | 35,000 | $1.23 | $43,050.00 | 2% 2.26M to 2.3M | |
| 30-Jan-24 9:05 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 30-Jan-24 | Planned Option Sale | 35,000 | $23.95 | $838,250.00 | (2%) 2.3M to 2.26M | |
| 19-Jan-24 8:35 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 19-Jan-24 | Option Exercise | 30,000 | $8.32 | $249,600.00 | 100% 0 to 30.0K | |
| 19-Jan-24 8:35 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 19-Jan-24 | Planned Option Sale | 30,000 | $23.05 | $691,500.00 | (100%) 30.0K to 0 | |
| 04-Jan-24 9:36 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Payment of Exercise | 14,199 | $18.58 | $263,817.00 | (4%) 348.0K to 333.8K | |
| 04-Jan-24 9:35 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Sale | 15,000 | $17.90 | $268,500.00 | (8%) 195.73K to 180.73K | |
| 04-Jan-24 9:37 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Payment of Exercise | 39,552 | $18.58 | $734,876.00 | (2%) 2.3M to 2.26M | |
| 04-Jan-24 9:35 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Payment of Exercise | 13,872 | $18.58 | $257,742.00 | (7%) 209.6K to 195.73K |
